$80,000 of SOLENO THERAPEUTICS INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption H.R.7118, Genomic Answers for Childrens Health Act; H.R.1414, Camerons Law; H.R.1492/S.832, EPIC Act; Most Favored Nation, orphan drug exemption"
You can find more data on corporate lobbying on Quiver Quantitative.
SLNO Insider Trading Activity
SLNO insiders have traded $SLNO stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $SLNO stock by insiders over the last 6 months:
- MEREDITH MANNING (Chief Commercial Officer) has made 0 purchases and 3 sales selling 7,522 shares for an estimated $228,979.
- MICHAEL F. HUANG (Sr. VP of Clinical Development) has made 0 purchases and 3 sales selling 6,582 shares for an estimated $200,364.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
SLNO Hedge Fund Activity
We have seen 142 institutional investors add shares of SLNO stock to their portfolio, and 134 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VIVO CAPITAL, LLC removed 1,383,294 shares (-60.7%) from their portfolio in Q4 2025, for an estimated $64,046,512
- JANUS HENDERSON GROUP PLC added 1,122,015 shares (+18.5%) to their portfolio in Q4 2025, for an estimated $51,949,294
- WELLINGTON MANAGEMENT GROUP LLP added 1,010,704 shares (+43.7%) to their portfolio in Q4 2025, for an estimated $46,795,595
- DEEP TRACK CAPITAL, LP added 1,000,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $46,300,000
- HOLOCENE ADVISORS, LP removed 997,069 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $46,164,294
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 899,157 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $41,630,969
- WOODLINE PARTNERS LP added 840,946 shares (+310.5%) to their portfolio in Q4 2025, for an estimated $38,935,799
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
SLNO Analyst Ratings
Wall Street analysts have issued reports on $SLNO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/20/2026
To track analyst ratings and price targets for SLNO, check out Quiver Quantitative's $SLNO forecast page.
SLNO Price Targets
Multiple analysts have issued price targets for $SLNO recently. We have seen 6 analysts offer price targets for $SLNO in the last 6 months, with a median target of $53.0.
Here are some recent targets:
- Derek Archila from Wells Fargo set a target price of $53.0 on 04/17/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $53.0 on 04/08/2026
- Tyler Van Buren from TD Cowen set a target price of $53.0 on 04/07/2026
- Kristen Kluska from Cantor Fitzgerald set a target price of $53.0 on 04/06/2026
- Leland Gershell from Oppenheimer set a target price of $80.0 on 03/18/2026
- Kalpit Patel from Wolfe Research set a target price of $75.0 on 11/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
